Albumin Supplementation Dampens Hypercoagulability in COVID-19: A Preliminary Report
Coronavirus disease 2019 (COVID-19) is characterized by
severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) needing mechanical ventilation and intensive care
unit (ICU) treatment. In addition to lung disease, clinical
features of SARS-CoV-2 include myocardial damage and
ischemia-related vascular disease, which are associated
with a hypercoagulable state (e.g., high D-dimer levels)